20. Receivables and prepayments (continued)

As at 31 December, the ageing analysis of trade receivables is as follows:

	Group		Company	
(all amounts in Euro thousands)	2015	2014	2015	2014
Neither past due but not impaired	56,421	59,427	24,770	30,868
Past due nor impaired :				
< 30 days	11,061	13,340	3,441	3,444
30-60 days	5,539	6,918	2,537	693
60-90 days	6,196	2,780	4,185	174
90-120 days	3,907	2,209	1,947	146
>120 days	18,832	10,614	8,176	1,532
	101,956	95,288	45,056	36,857

Part of the aforementioned trade receivables is secured by guarantees/collaterals, amounting to €27,819 thousand (31.12.2014: €22,743 thousand) for the Group and €10,716 thousand (31.12.2014: €16,638 thousand) for the Company (note 31).

Trade receivables are non-interest bearing and are normally settled on 30-170 days for the Group and the Company.

Allowance for doubtful debtors analysis	Group		Company	
(all amounts in Euro thousands)	2015	2014	2015	2014
Balance at 1 January	29,136	30,421	4,466	7,165
Charge for the year (note 29)	3,062	3,652	276	403
Unused amounts reversed (note 29)	-2,269	-2,834	-284	-843
Utilized	-774	-4,047	-212	-2,259
Reclassification from other receivables/payables	71	96	-	-
Additions due to acquisitions	-	1,251	-	-
Exchange differences	624	597	-	
Balance at 31 December	29,850	29,136	4,246	4,466

The individually impaired receivables mainly relate to wholesalers, which are in unexpectedly difficult economic situations. It was assessed that a portion of the receivables is expected to be recovered.

21. Cash and cash equivalents

	Gro	oup	Company		
(all amounts in Euro thousands)	2015	2014	2015	2014	
Cash at bank and in hand	428	86	281	7	
Short-term bank deposits	121,305	142,860	8,345	16,964	
	121,733	142,946	8,626	16,971	

Short-term bank deposits comprise primarily of current accounts and time deposits. The effective interest rates on these short-term bank deposits are based on floating rates and are negotiated on a case by case basis.

22. Share capital and premium

(all amounts are shown in Euro thousands unless otherwise stated)

The total number of the authorized ordinary shares is:

Ordinary shares of €4.00 each Preference shares of €4.00 each

Group & Company					
2015 2014					
77,063,568	77,063,568				
7,568,960	7,568,960				
84,632,528	84,632,528				

22. Share capital and premium (continued)

(all amounts are shown in Euro thousands unless otherwise stated)

	Ordinary	shares	Preference shares		Preference shares		Preference shares		Preference shares		Preference shares			Total	
Shares issued and fully paid	Number of shares	€'000	Number of shares	€'000	Share premium €'000	Number of shares	€'000								
Balance at 1 January 2014	77,063,568	308,254	7,568,960	30,276	22,826	84,632,528	361,356								
Balance at 31 December 2014	77,063,568	308,254	7,568,960	30,276	22,826	84,632,528	361,356								
Balance at 31 December 2015	77,063,568	308,254	7,568,960	30,276	22,826	84,632,528	361,356								

	Ordinary	shares	Preference shares		Total	
Treasury shares	Number of shares	€'000	Number of shares	€'000	Number of shares	€'000
Balance at 1 January 2014	3,061,415	87,563	5,919	117	3,067,334	87,680
Treasury shares sold	-141,503	-4,047		-	-141,503	-4,047
Balance at 31 December 2014	2,919,912	83,516	5,919	117	2,925,831	83,633
Treasury shares sold	-159,319	-4,556		-	-159,319	-4,556
Balance at 31 December 2015	2,760,593	78,960	5,919	117	2,766,512	79,077

For the year 2015, the average stock price of Titan Cement Company S.A. ordinary shares was €20.40 (2014: €21.50) and the closing price of the ordinary shares at December 31, 2015 was €17.61 (2014: €19.17).

Share options

Share options are granted to members of senior management. Movements in the number of share options outstanding are as follows:

	2010 scheme	2014 scheme
Balance at 1 January 2014	659,898	-
Granted	-	250,190
Exercised	-141,503	-
Non vested	-118,977	-
Cancelled	-14,209	-
Balance at 31 December 2014	385,209	250,190
Granted	-	313,080
Exercised	-159,319	-
Non vested	-61,112	-
Cancelled	-17,545	-4,750
Balance at 31 December 2015	147,233	558,520

Share options outstanding at the end of the year have the following terms:

	2010 sc	heme	2014 scheme		
Exercise price	£ 4.	00	£ 10.	.00	
	2014 2015		2014	2015	
Expiration date					
2015	25,629	-	-	-	
2016	359,580	147,233	-	-	
2020	-	-	250,190	247,540	
2021	-	-		310,980	
	385,209	147,233	250,190	558,520	

22. Share capital and premium (continued)

2010 Programme

On June 3, 2010 the Company approved the introduction of a new, three-year Stock Option Programme (2010 Programme). In the years 2010, 2011 and 2012, executive members of the Company's Board of Directors and senior executives of the Company and its affiliates in Greece and abroad were granted options, vesting of which is subject to the financial results of the Company and the performance of its ordinary share, to acquire up to 1,000,000 ordinary shares of the Company at a sale price equal to the share's nominal value, that is €4.00 per share.

Under this Programme, the options granted each year have a maturity period of three years and can be exercised within two years after the completion of the three year period. Each option must be exercised within the year following the one in which the final number of options that can be exercised is determined. If the deadline is exceeded, those particular options will irrevocably lapse. All vesting is conditional upon the employees' continued employment throughout the vesting period. The number of options that vest each year will be determined as follows:

1) One-third of options granted vest based on the financial results of the Company.

2) One-third of options granted vest based on Titan Cement's stock performance relative to three Athens Stock Exchange indices during the three year period.

3) One-third of options granted vest based on Titan Cement's stock performance relative to that of ten predefined international cement producing companies during the three year period.

The options granted under the 2010 Programme have been accounted for in terms of the requirements of IFRS 2 "Share based payments". The number of Share Options that were granted during 2010, 2011 and 2012 was 267,720, 301,200 and 376,290 respectively.

The fair value of the options granted in 2010, determined using the Monte Carlo Simulation valuation model, was \leq 5.36 per option. The significant inputs used in the application of the valuation model were share price at grant date of \leq 15.90, standard deviation of share price of 39.42%, dividend yield of 2.68% and the rate of the three-year fixed EUR swap interest rate of 2.25%.

The fair value of the options granted in 2011 was ≤ 6.86 per option, determined using the Monte Carlo Simulation valuation model. The significant inputs used in the application of the valuation model were share price at grant date of ≤ 17.88 , standard deviation of share price of 43.98%, dividend yield of 2.74% and the rate of the three-year fixed EUR swap interest rate of 1.89%.

The fair value of the options granted in 2012 was \leq 3.05 per option, determined using the Binomial Method and the Monte Carlo Simulation valuation model. The significant inputs used in the aforementioned methodology were the share price at grant date of \leq 14.72, the volatility of the share price estimated at 37.4%, the dividend yield of 0.7% and the yield of the 3 year EU Benchmark (Deutsche Bund) Government bond yield rate of 0.32%.

As of December 31th 2015, the number of the cancelled share options that were granted during 2010, 2011 and 2012 is 13,380, 17,910 and 16,710 respectively whereas the respective number of the share options that were not vested is 190,746, 118,977 and 61,112.

Out of the share options that were granted during 2010, 8,684 vested and cancelled. The remaining 54,910 share options, that represent 0.06% of Company's total shares of the paid up share capital, were exercised (2013: 50,282 / 2014: 4,628) by 75 Group executives, including 5 executive Board members of the Company. Total purchase cost of common treasury shares of the Company amounted \leq 1,898 thousand (2013: \leq 1,766 thousand / 2014: \leq 132 thousand). The sale price of the Company's common treasury shares (over-the-counter-transaction) equaled to the nominal value of each Company share, i.e. \leq 4.00. The total share price amounted \leq 220 thousand. The loss caused by this transaction amounted to \leq 1,678 thousand (2013: \leq 1,565 thousands / 2014: \leq 113 thousands) and were attributed to the equity holders of the Company.

Out of the share options that were granted during 2011, 15,494 vested and cancelled. The remaining 148,819 share options, that represent 0.17% of Company's total shares of the paid up share capital, were exercised (2014:136,875 / 2015:11,944) by 87 Group executives, including 6 executive Board members of the Company. Total purchase cost of common treasury shares of the Company amounted \leq 4,257 thousand (2014: \leq 3,915 thousand / 2015: \leq 342 thousand). The sale price of the Company's common treasury shares (over-the-counter-transaction) equaled to the nominal value of each Company share, i.e. \leq 4.00. The total share price amounted \leq 595 thousand. The loss caused by this transaction amounted to \leq 3,662 thousand (2014: \leq 3,368 thousands / 2015: \leq 294 thousands) and were attributed to the equity holders of the Company.

Out of the share options that were granted during 2012, 3,860 vested and cancelled and as of December 31th 2015, 147,233 share options remain unexercised. During 2015, the remaining 147,375 share options, that represent 0.17% of Company's total shares of the paid up share capital, were exercised by 69 Group executives, including 1 executive Board member of the Company. Total purchase cost of common treasury shares of the Company amounted €4,214 thousand. The sale price of the Company's common treasury shares (over-the-counter-transaction) equaled to the nominal value of each Company share, i.e. \in 4.00. The total share price amounted €590 thousand. The loss caused by this transaction amounted to €3,624 thousand and were attributed to the equity holders of the Company.

22. Share capital and premium (continued)

2014 Programme

Beneficiaries of the Stock Option Plan are the executive members of the Board of Directors of the Company, the managers and the employees who have the same rank in affiliated companies inside and outside Greece and finally a limited number of the other employees who stand out on a continuous basis for their good performance and have a high potential for advancement.

The vesting period of the stock options that were granted in 2014, 2015 and those that will be granted in 2016 shall be three years. Therefore, the relevant option rights shall become mature in December of 2016, 2017 and 2018 respectively, provided that the beneficiaries are still employees of the Group. After the completion of the three-year vesting period, the final option rights number, which the beneficiaries will be entitled to exercise, shall be determined by the Board of Directors, within the first four months of 2017, 2018 and 2019 respectively and shall depend:

a) By 50% on the average three year Return on Average Capital Employed (ROACE) compared to the target of each year period, as this will be determined by the Board of Directors before granting the relevant option rights.

b) By 50% on the overall performance of the Company's common share compared to the average overall performance of the shares of the ten predefined international cement producing companies.

The Beneficiaries shall be entitled to exercise their stock option rights, either in whole or in part, within the first five days of each month, paying the Company the relevant amounts until the expiration date of their stock options, i.e. until December of the third year after these stock options have been vested.

The options granted under the 2014 Programme have been accounted for in terms of the requirements of IFRS 2 "Share based payments".

The number of Share Options that were granted during 2014 and 2015 was 250,190 and 313,080 respectively.

The fair value of the options granted in 2014 was \notin 7.39 per option, determined using the Binomial Method and the Monte Carlo Simulation valuation model. The significant inputs used in the aforementioned methodologies were the share price at grant date of \notin 25.32, the employee forfeiture rate 9.2%, the volatility of the share price estimated at 47.2%, the dividend yield of 0.376% and the yield of the 3 year EU Benchmark (Deutsche Bund) Government bond yield rate of 0.083%.

The fair value of the options granted in 2015 was \leq 4.14 per option, determined using the Binomial Method and the Monte Carlo Simulation valuation model. The significant inputs used in the aforementioned methodologies were the share price at grant date of \leq 19.55, the employee forfeiture rate 9.2%, the volatility of the share price estimated at 40.61%, the dividend yield of 0.59% and the yield of the 1 year EURIOBOR rate of 0.166%.

As of 31th of December 2015 2,650 and 2,100 share options that were granted in 2014 and 2015 respectively have been cancelled.